The pharmaceutical giant Eli Lilly is reportedly holding discussions to acquire AtaiBeckley, a New York firm specializing in psychedelic therapies. The deal could be announced as soon as this week, and AtaiBeckley's shareholders are looking at a premium on the current stock price.
The company is worth about $2 billion right now.
Lilly has been in the neuroscience game for decades. It was the company behind Prozac, which changed how doctors treat depression three decades ago. Now it wants to add a faster tool to its lineup.
The shift toward rapid-acting treatments in the industry is what draws Lilly to psychedelics. Traditional antidepressants like Prozac often take weeks to show effect, while BPL-003's two-day improvement could transform patient care. The FDA's Breakthrough Therapy designation further validates the approach, and Johnson & Johnson's Spravato has already proven the commercial model works for psychedelic-derived medications.
AtaiBeckley's most promising candidate is BPL-003, a psychedelic compound that produces a trip lasting roughly one to two hours.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Compare that to a competing treatment from Compass Pathways. Their drug requires up to eight hours of monitoring because the psychedelic experience lasts longer. BPL-003 is shorter and simpler to manage.
During a recent meeting at Bloomberg's New York headquarters, CEO Srinivas Rao stated, "Our aim is to create a treatment that is patient friendly and doctor friendly." He described it as a treatment that could "drag and drop into the Spravato paradigm." Spravato is a psychedelic-derived nasal spray from Johnson & Johnson.
The US Food and Drug Administration gave BPL-003 a Breakthrough Therapy designation, which speeds up the review process.
Lilly's history with Prozac - introduced in the late 1980s - transformed depression care by targeting serotonin reuptake, but its delayed onset has long been a limitation. Now, with BPL-003 showing rapid effects, Lilly aims to bridge that gap using its established psychiatric medicine infrastructure.
The psychedelic medicine field is gaining momentum for a few reasons. Johnson & Johnson's Spravato proved the model works. Positive trial results keep rolling in. And there has been recent support from the Trump administration.
Lilly is not the only big pharma player circling. AbbVie is also active in psychedelics. Compass Pathways is running its own trials.
If the deal goes through, AtaiBeckley shareholders get a premium. But the bigger picture is about where the mental health industry is heading.
Psychedelic compounds offer a different path: fast results and less time in a doctor's office.
For investors, this move signals that big pharmaceutical companies see psychedelics as more than a fringe bet. When Eli Lilly writes a check for a company like AtaiBeckley, it is betting that the science is real and the market is ready.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
